The stock of Astrazeneca plc ADR (AZN) has seen a -1.95% decrease in the past week, with a -18.96% drop in the past month, and a -25.42% decrease in the past quarter. The volatility ratio for the week is 2.11%, and the volatility levels for the past 30 days are at 1.79% for AZN. The simple moving average for the past 20 days is -9.90% for AZN’s stock, with a -15.40% simple moving average for the past 200 days.
Is It Worth Investing in Astrazeneca plc ADR (NASDAQ: AZN) Right Now?
Astrazeneca plc ADR (NASDAQ: AZN) has a price-to-earnings ratio of 30.39x that is above its average ratio. Additionally, the 36-month beta value for AZN is 0.47. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AZN is 3.10B and currently, short sellers hold a 0.15% ratio of that float. The average trading volume of AZN on November 18, 2024 was 4.98M shares.
AZN) stock’s latest price update
Astrazeneca plc ADR (NASDAQ: AZN)’s stock price has decreased by -2.78 compared to its previous closing price of 65.04. However, the company has seen a -1.95% decrease in its stock price over the last five trading sessions. accesswire.com reported 2024-11-16 that NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC (“AstraZeneca PLC”) (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
Analysts’ Opinion of AZN
Goldman gave a rating of “Buy” to AZN, setting the target price at $97 in the report published on May 30th of the current year.
AZN Trading at -15.73% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.88% of loss for the given period.
Volatility was left at 1.79%, however, over the last 30 days, the volatility rate increased by 2.11%, as shares sank -19.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.87% lower at present.
During the last 5 trading sessions, AZN fell by -1.95%, which changed the moving average for the period of 200-days by -5.42% in comparison to the 20-day moving average, which settled at $70.18. In addition, Astrazeneca plc ADR saw -6.12% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.77 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.13. The total capital return value is set at 0.12. Equity return is now at value 16.67, with 6.46 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at 0.38. The debt to equity ratio resting at 0.74. The interest coverage ratio of the stock is 5.48.
Currently, EBITDA for the company is 12.98 billion with net debt to EBITDA at 1.73. When we switch over and look at the enterprise to sales, we see a ratio of 4.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.93.
Conclusion
In conclusion, Astrazeneca plc ADR (AZN) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
